Two months after MSD (Merck & Co) set its eye on acquiring Eyebiotech (EyeBio), the former has closed the deal, making EyeBio its subsidiary.
MSD has acquired all outstanding shares of the privately held UK-based biotech through a subsidiary as part of the agreement. EyeBio鈥檚 shareholders will receive approximately $0.50 per share, totalling $1.3bn.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Following the acquisition, MSD has gained access to EyeBio鈥檚 lead asset Restoret (EYE-103), a tetravalent, tri-specific antibody that targets the Wingless-related integration site (Wnt) signalling pathway.
A Phase IIb/III trial investigating Restoret in patients with DME is expected to begin in H2 this year. In February, EyeBio reported positive data from the (NCT05919693) in patients with treatment-na茂ve diabetic macular oedema (DME) and treatment-naive neovascular age-related macular degeneration (AMD).
In the study, Restoret improved vision in 26 participants with DME, leading to an improved best-corrected visual acuity by +11.2 letters and a mean reduction in retinal thickness of -143 碌m. Similar outcomes were observed in the five treatment-naive neovascular AMD participants who received Restoret in combination with Regeneron 色界吧s鈥� . The therapy was well tolerated, with no treatment-related adverse events.
In the past few months, MSD has invested considerable resources in expanding its therapeutics portfolio through acquisitions and partnerships. In March, MSD acquired US-based Harpoon Therapeutics to bolster its immunology pipeline. The company gained access to Harpoon鈥檚 T cell engagers 鈥� engineered antibodies that redirect T cells to attack cancer cells.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn November 2023, the company acquired US-based Caraway Therapeutics to expand its pipeline for neurogenerative disease therapies. Caraway鈥檚 portfolio comprised a preclinical candidate that targets the transient receptor potential cation channel subfamily (TRPML1). The compound is being evaluated as a treatment for the lysosomal storage disorder, Gaucher disease, and glucocerebrosidase (GBA)-mutated Parkinson鈥檚 disease.
In October 2023, MSD signed a licensing agreement with Daiichi Sankyo to develop and commercialise three antibody-drug conjugate candidates.
